The global digital therapeutics market is projected to be worth over USD 8.86 billion by 2030, growi
Recent advances in information technology and biomedical science have enabled the development of a number of versatile digital solutions that are capable of either mimicking or augmenting, the fundamental qualities of pharmacological interventions
Roots Analysis has announced the addition of “Digital Health Market: Focus on Digital Therapeutics (2nd Edition), 2020-2030 (Based on Type of Solution (Software Solution, Gaming Solution and Combination Solution), Type of Therapy (Curative and Preventive), and Purpose of Solution (Medication Replacement and Medication Augmentation” report to its list of offerings.
According to experts, digital therapeutic solutions are primarily based on behavior modification and are designed to address a variety of therapeutic needs across a wide range of disease indications. On the other hand, several digital solutions have been developed to enable remote doctor-patient consultations. Such solutions witnessed a surge in adoptions amidst the COVID-19 pandemic.
To order this 500+ page report, which features 160+ figures and 200+ tables, please visit this – https://www.rootsanalysis.com/reports/view_document/digital-health-market/208.html
Key Market Insights
Nearly 230 digital therapeutic solutions are currently available / under development
Close to 45% of the aforementioned solutions are standalone software applications targeting more than 60 unique indications.
Over 85% of digital therapeutic solutions are intended to replace medication
Such solutions are currently available / being developed to treat neurological disorders (27%), mental health problems (24%), and certain metabolic disorders (24%). Alternatively, some digital health products are designed to augment the effect of conventional therapeutics and are currently being considered for treating substance use disorders and few mental health problems.
220+ clinical trials, focused on digital therapeutics, have been registered since 2004
Around 80,000 patients have been enrol